In the next section, we report our experiments in DLBCL cell lines, where we tested whether the manipulation of BECLIN-1 or BCL-2 expression and function effectively impact doxorubicin sensitivity and autophagy-associated cell death. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.